Medivisor Inc. (MVSR) provides a broad range of outsourced marketing and sales services to pharmaceutical and life sciences companies. The Company uses the most advanced communication channel in the industry - electronic detailing (e-detailing) - to promote pharmaceutical products to physicians and to inform medical professionals of medical advances. The Company creates a variety of educational and informational presentations and distributes it through the Internet, video conferencing and interactive voice response to the mutual benefit of both the pharmaceutical vendors and healthcare practitioners.

MVSR is entering into exclusive arrangements with drug manufacturers to market their products in return for a share of the profits from drug sales. The Company has an agreement with New Jersey-based Cura Pharmaceutical to market Albumax, a whey protein isolate formula that allows patients with kidney disorders to achieve daily protein requirements, as well as MucotrolTM, an oral gel wafer for treating mouth sores resulting from chemotherapy. Albumax has been approved by the New York, California and Pennsylvania state Medicaid offices, while MucotrolTM has 510-K approval from the FDA. MVSR recently signed an agreement giving the Company exclusive rights to distribute Albumax in Italy. The annual worldwide markets for MucotrolTM and Albumax are estimated at $250 million and $120 million, respectively.

In addition, MVSR recently signed a revenue-sharing agreement with PanGenex Corp. for the marketing and sale of LipidemeTM, which is the first product on the market combining the triglyceride-lowering power of omega-3 fatty acids with the cholesterol-lowering ability of phytosterols and tocotrienols, as well as the free-radical fighting abilities of Coenzyme Q10. This product addresses a potential U.S. market consisting of nearly 140 million Americans with borderline-high or high cholesterol levels. The Company is also poised to launch an energy drink in the European market that contains Acai, a top superfood with extraordinary health benefits.

Business model focusing on marketing pharmaceuticals

MVSR delivers comprehensive marketing strategies to help pharmaceutical manufacturers communicate key scientific findings to the medical community. The Company’s services are designed to help pharmaceutical companies reach key audiences and increase sales of new and current drugs. MVSR works with pharmaceutical companies, health care organizations, medical suppliers and distributors.

In 2006, global spending on prescription drugs topped $643 billion, growing 10% annually between 1999 and 2006. North America accounted for the largest percentage of the world market (45%), and Europe second at 23% of total global sales.

Digital technology enhances marketing effort

With the pharmaceuticals industry spending more than $14 billion annually on detailing, there is increased pressure on pharmaceutical companies to find new, profitable ways to reach physicians and build revenues.

MVSR employs e-detailing, which refers to the use of digital technology such as Internet, tele/video conferencing and Interactive Voice Response, to enhance or replace the pharmaceutical representatives’ traditional sales call on healthcare providers, maximize sales force productivity, reduce costs and increase physician prescribing. Through e-detailing, MVSR provides an Internet venue where vendors can “detail” and clinicians can absorb published scientific, technical, or medical information that is relevant to the product and available on-demand. In addition, the Company provides appropriate honorariums to show appreciation for the professional’s time spent reading or listening to the presentation.

Cura Pharmaceutical agreements

MVSR has secured agreements with Cura Pharmaceutical to market Albumax, a whey protein isolate formula that helps patients with kidney disorders obtain their daily protein requirements, and MucotrolTM, an oral gel wafer that soothes mouth sores related to chemotherapy.

Albumax has been approved by the New York, California and Pennsylvania state Medicaid offices. MucotrolTM received FDA approval in November 2004. Albumax addresses a $120 million worldwide market, while the market for MucotrolTM is estimated at $250 million.

Revenue-sharing agreement with PanGenex

The American Heart Association estimates that nearly 140 million Americans have either borderline-high or high cholesterol levels. In 2003, approximately 22 million people took a medication to try to lower their cholesterol.

MVSR recently signed a revenue-sharing agreement with PanGenex Corp. for the marketing and sale of LipidemeTM. LipidemeTM is the first product on the market to combine the triglyceride-lowering power of omega-3 fatty acids with the cholesterol-lowering ability of phytosterols and tocotrienols, plus the free-radical fighting abilities of Coenzyme Q10. Because these four ingredients tackle different aspects of cardiovascular health, Lipideme’s synergistic blend is far superior to single-ingredient products.

Entry into the energy drink market

The Company is also preparing to launch its own energy drink in the billion dollar energy drink market. The Company’s energy drink contains Acai, one of the world's top superfoods. The extraordinary health benefits of Acai, which include superior nutrient content and unmatched antioxidant levels, have been validated by scientific studies.

Energy drinks are the fastest-growing segment of the beverage market. Since 2003, the energy drink market has grown 440% to $6.6 billion in 2007 and is expected to reach $9 billion in 2011.

Strong revenue growth outlook

The revenue-sharing agreements with Cura Pharmaceuticals, PanGenex and the energy drink market initiative should fuel robust revenue growth for MVSR. We expect the Company to record 2009 revenues in a $6 million range and maintain 40%-50% annual growth over the next three to five years. MVSR anticipates reaching breakeven in the second half of 2009.